Methods: Mice and jirds were vaccinated with monovalent DNA preparations of BmVAL-1 or BmALT-2 in pVAX-1 vector or monovalent protein preparations of rBmVAL-1 and rBmALT-2 in alum using a homologous or heterologous prime boost approach. These vaccine regimens were then compared with a multivalent vaccine formulation consisting of DNA or hybrid protein formulation of the two antigens.
Methods:
Mice and jirds were vaccinated with monovalent DNA preparations of BmVAL-1 or BmALT-2 in pVAX-1 vector or monovalent protein preparations of rBmVAL-1 and rBmALT-2 in alum using a homologous or heterologous prime boost approach. These vaccine regimens were then compared with a multivalent vaccine formulation consisting of DNA or hybrid protein formulation of the two antigens.
Challenge experiments were performed with B. malayi L3 in mice and jirds to evaluate the degree of protection and immunological parameters were determined in mice and human to elucidate the characteristics of the protective immune responses.
Results:
Results presented in this study show that vaccination with monovalent BmVAL-1 vaccine confers from 39% (DNA vaccine) protection to 54% (DNA prime and protein boost) protection in mice. Similar degree of protection was observed in jirds (50% to 52% protection). Monovalent BmAT-2 afforded 51% to 75% protection in mice and 58% to 79% protection in jirds. When we tested a multivalent formulation of BmVAL-1 and BmALT-2, there was 57% to 82% protection in mice and 77% to 85% protection in jirds.
Heterologous prime boost approach using the multivalent vaccine gave the highest degree 
Conclusion:
In conclusion, results presented in this study show that a multivalent vaccine formulation of BmVAL-1 and BmALT-2 when given as a prime boost regimen gave significant protection against lymphatic filariasis caused by B. malayi in mice and jirds. Since putatively immune EN subjects also carry protective antibodies against BmVAL-1 and BmALT-2, there is a great potential for developing this multivalent formulation as a prophylactic vaccine against B. malayi for human and veterinary use. The ultimate goal is to eliminate the disease by 2020. MDA strategy is showing high success in several parts of the world. Despite its initial success, some endemic regions have already started facing significant difficulties in implementing the MDA program due to political unrest or lack of compliance. [4] [5] [6] [7] To be effective MDA need to be repeated annually at least for 5 years (WHO). Vector control measures are not as successful as treating the patient for controlling the infection. However, since vector population is very high in these regions, multiple treatments with MDA are necessary for consistent protection. Multiple administrations of drugs, especially albendazole in the MDA regimen raises concern because of the potential for drug resistance. In fact, resistance to benzimidazole group of drugs has already been reported in B. malayi and W. bancrofti. 8 Thus, repeated administration of albendazole each year in the endemic region may not an ideal situation. A more practicable and sustainable approach to prevent this infection in a large population would be a prophylactic vaccination possibly with simultaneous mass screening and treating infected individuals with DEC or combination drugs such as that used in MDA.
Protective immunity against lymphatic filarial parasite has been demonstrated in both human and animals. 9, 10 Certain individuals living in the endemic areas under the same environmental conditions as the infected individuals do not show any symptoms of the disease, but carry high titer of antibodies against the filarial parasites in their sera.
Previous studies from our laboratory showed that these circulating antibodies can participate in the killing of infective third stage (L3) B. malayi larvae in vitro through an antibody dependent cell cytotoxicity (ADCC) mechanism. 11 Similarly, animal studies also showed that vaccination with irradiated third stage larvae (L3) of B. malayi confer significant protection against challenge infections. These findings provided strong evidence that protective immunity against B. malayi and W. bancrofti can be induced in human and animals. However, identifying the host protective antigens and the development of a suitable vaccine against lymphatic filariasis has been severely hampered by the complicated life cycle of the parasite and the difficulty in maintaining W. bancrofti life cycle stages under laboratory conditions. Despite these difficulties several potential candidate vaccine antigens are reported from many laboratories. [11] [12] [13] [14] Completion of the B. malayi genome substantially boosted the vaccine antigen discovery.
Using a phage display-based iterative screening of a B. malayi L3 cDNA library with immune human sera, our laboratory previously showed that B. malayi vespid venom allergen homologue-like protein (BmVAL-1) and B. malayi Abundant Larval Transcript -2 (BmALT-2) are potential vaccine candidates. 13 Vaccine potential of both BmVAL-1 (BmVAL-1) and ALT-2 has already been reported previously by other groups. [15] [16] [17] [18] Thus, the powerful phage display-based parasite cDNA expression library screening confirmed previous reports and narrowed down the candidate vaccine antigens to VAL-1 and ALT-2. VAL-1 belongs to a family of proteins called Ancylostoma caninum secreted proteins or the ASP. 
MATERIALS AND METHODS

Sera
Sera samples used in this study were from archived samples stored at the Mahatma Gandhi Institute of Medical Sciences, Sevagram, India. These samples were collected as part of epidemiological surveys in and around Wardha, an area endemic for lymphatic filariasis. Use of human subjects in this study and the protocols and the consent forms No demographic data was available to this study except that the sera samples were classified into microfilaremic (MF), chronic pathology (CP) or Endemic normals (EN) based on the detection of circulating parasites, parasite antigens or by evaluating clinical symptoms of lymphatic filariasis. Circulating microfilariae were detected in the blood of subjects as described previously. 11, 13 The presence of circulating antigen was detected using an Og4C3 kit and a WbSXP-based enzyme-linked immunosorbent assay (ELISA).
Subjects with no circulating antigen or microfilariae were classified as EN, whereas subjects with circulating microfilariae and/or circulating antigen, as detected by ELISA, were considered as MF. Subjects showing lymphedema and other visible clinical symptoms of filariasis were grouped into CP. Control non-endemic normal (NEN) sera were collected at the University of Illinois Clinic at Rockford, IL.
Parasites
Brugia malayi L3s were obtained from the NIAID/NIH Filariasis Research Reagent Resource Center (FR3) at the University of Georgia, Athens, GA
Construction of monovalent and multivalent DNA vaccines:
To prepare monovalent vaccine, codon optimized BmVAL-1 (Acc: AF042088) or Bmalt-2 (Acc: U84723) genes were cloned into the eukaryotic expression vector pVAX1 (Invitrogen, Carlsbad, CA) using insert specific primers. 13, 24 To prepare multivalent vaccine, codon optimized BmVAL-1 gene was first cloned into pVAX1 vector with no stop codon using already published primer sequences with a pst I site. Codon optimized Bmalt-2 gene was then inserted into this clone using gene specific primers. PCR parameters for all the constructs were: 94°C denaturation for 30 s, 50°C primer annealing for 30 s, 72°C primer extension for 30 s for 30 cycles; a final extension of 5 min was performed at 72° C. Insert DNA was finally sequenced to ensure authenticity of the cloned nucleotide sequence on both strands. Plasmids were maintained and propagated in E.coli Top10F cells. Plasmids were purified using endotoxin free plasmid extraction kit (Qiagen, Valencia, CA). DNA was analyzed by agarose gel electrophoresis and quantified in a spectrophotometer (OD 260/280, ratio>1.8).
Expression and Purification of recombinant proteins
Recombinant BmVAL-1 and rBmALT-2 were expressed in pRSET-A vector and purified using an immobilized cobalt metal affinity column chromatography as described previously from our laboratory. 17, 18 Endotoxin in the recombinant preparations were removed by passing the recombinant proteins through polymyxin B affinity columns (Thermo Fisher Scientific, Rockford, IL) and the levels of endotoxin in the final preparations were determined using an E-TOXATE kit (Sigma, St Louis, MO) as per manufacturer's instructions. Endotoxin levels in the final preparations (0.005 EU/ml) were below detection limits in these recombinant protein preparations.
Immunoreactivity of the various human sera
To determine if the human sera samples carries antibodies against BmVAL-1 or BmALT-2, we performed an ELISA as described before. 11, 13 For isotype specific ELISA, alkaline phosphatase conjugated goat anti-human IgG1, anti-human IgG2, anti-human IgG3, and anti-human IgG4 antibodies (Sigma) were used as the secondary antibodies.
Immunization protocol for mice and jirds
Six-week old male Balb/c mice and 35-40 gm outbred male mangolian gerbils (jirds) purchased from Charles River Laboratories (Wilmington, MA) were used in these experiments. Animals were treated as per the guidelines in the Guide for the Care and Use of Laboratory Animals. Humane use of animals in this study and the protocol was approved by the IACUC committee at the College of Medicine, University of Illinois Rockford. The reason for using two different animal models to test the vaccine formulations is that the B. malayi parasite does not mature into adults in mouse, so vaccine-induced protection against the L3 stages can be evaluated in the mouse model. In addition, significant immunological parameters can be measured in mice. Conversely, B.
malayi parasite develops into mature adult worms in jirds. Therefore, we can evaluate vaccine-induced protection against adult worm establishment in jirds.
There were three sets of experiments (1) 
7. Protection studies in mice:
Challenge studies were conducted in mice by surgically implanting twenty B. malayi live infective L3s into the peritoneal cavity in a micropore chamber as described previously. 11, 25 Aseptic conditions were followed for the surgical procedures. 48 hours after implantation, chambers were recovered from the peritoneal cavity and viability of the larvae was determined under a light microscope. The percentage of protection was expressed as the number of dead parasites  number of total parasites recovered x 100.
Splenocyte proliferation and cytokine assays
Single cell suspension of spleen cells (0.5x 10 6 cells per well suspended in 200l media)
were prepared from each mouse and cultured in triplicate wells with either (1) 1g/ml rBmVAL-1, (2) 1g/ml rBmALT-2, (3) 1g/ml rBmVAL-1+BmALT-2, (4) a nonspecific recombinant protein (1g/ml of Schistosoma mansoni G-binding protein) or (5) were left unstimulated in the media. All cells were incubated for 3 days at 37 
BmVAL-1 and BmALT-2 specific IgG antibodies in the sera of immunized mice
Titer of anti-BmVAL-1 and anti-BmALT-2 specific antibodies was determined in the sera of immunized mice using an ELISA as described previously. 11, 13 Pre immune sera served as controls. HRP conjugated goat anti-mouse IgG was used as the secondary antibody (Thermo Fisher Scientific) for mouse assay. OPD (Sigma) was used as the substrate and optical density (OD) was measured at 405nm.
Anti-BmVAL-1 and anti-BmALT-2 specific IgG1, IgG2a, IgG2b, IgG3 and IgG4 antibodies were determined in the sera of mouse using a mouse antibody isotyping kit purchased from Thermo Fisher Scientific. All ELISAs were performed as per the manufacturer's recommendation and absorbance was read at 405nm. Respective HRPlabeled goat anti-IgG isotype antibody was used as the secondary antibodies and color was developed using OPD substrate.
Challenge studies in jirds
Jirds were challenged with 100 B. malayi L3s and worm establishment was determined on day 95 after challenge as described previously. 26 Jirds are permissive hosts for B.
malayi and the worms mature into adult males and females in about 75 days. Presence of mature worms in the control group of jirds was confirmed by demonstrating microfilariae in their blood on day 80 after challenge. Percent reduction in the worm establishment was calculated using the formula: average number of worms recovered from control wormsaverage number of worms recovered from vaccinated animals / average number of worms recovered from control animals x 100.
Statistical analysis
Statistical analysis was performed using Sigmastat program (Jandel Scientific, San Rafel, California) and Statview (SAS Institute, Cary, NC.) software. Wilcoxon signed rank test was used to compare paired data; comparison between the groups was performed using the Mann-Whitney U test. p value of p<0.05 was considered statistically significant.
RESULTS
EN individuals carry high titer of antibodies against BmVAL-1 and BmALT-2
Significant anti-BmVAL-1 and anti-BmALT-2 IgG antibodies were present in the sera of EN subjects compared to MF subjects (p < 0.01) and CP subjects (p < 0.005) ( Figure   2A ). NEN subjects did not carry IgG antibodies against both the antigens. Subsequent analysis of the IgG isotype of antibodies in the sera of EN subjects showed that antiBmVAL-1 and antiBmALT-2 antibodies were predominantly of IgG1 and IgG3 isotypes ( Figure 2B ).
High titer of antibody responses in the sera of immunized mice:
Previous studies from our laboratory showed that mice vaccinated with B. malayi antigens elicited significant host protective IgG antibodies 11, 13, 24 . Therefore, in this study, we mainly focused on measuring IgG antibody titers in the sera of immunized mice.
Monovalent immunization with BmVAL-1 ( Figure 3A ) and monovalent immunization with Bmalt-2 ( Figure 3B ) both elicited significant (p< 0.005) titers of anti-BmVAL-1 and anti-BmALT-2 IgG antibodies in the sera of mice. Compared to controls, the prime boost immunized group gave the maximum titer of antibodies followed by protein immunized and DNA immunized groups (Figure 3) . Immunization with the multivalent vaccine formulation (BmVAL-1 + BmALT-2) also elicited significant IgG antibody titers against both rBmVAL-1 and rBmALT-2 ( Figure 3C ) and the titers were comparable suggesting that the antigens do not interfere each other or compete for dominance. An interesting finding was that the multivalent vaccine elicited significantly higher (p< 0.001) titer of IgG antibodies in mice compared to any of the monovalent vaccines (Figure 3 ). These finding suggested that the two antigens in the multivalent formulation synergistically increase the vaccine-induced antibody responses.
Overall, protein vaccination elicited higher titer of IgG antibodies compared to DNA vaccines suggesting that protein vaccinations are highly immunogenic (Figure 3 ). This may be partially due to the adjuvant used along with the protein vaccine. Another observation was that a heterologous prime boost approach gave a higher seroconversion than homologous prime boost approach (Figure 3) . Thus, overall heterologous prime boost approach appeared to stimulate the highest titer of antibodies.
IgG antibody subset analysis showed that BmVAL-1 vaccination elicited primarily IgG1 
Antigen-specific responses in the spleen of mice
Spleen cells from immunized mice stimulated with either rBmVAL-1 or rBmALT-2 proliferated significantly (SI 10.8 + 1.1 and SI 14.6 + 1.2 respectively) compared to the media control (SI 2.1+0.9). Spleen cells from mice immunized with the multivalent construct responded to both rBmVAL-1 (SI 18.9 + 2.6) and rBmALT-2 (SI 23.5 + 3.1) suggesting that a strong recall cellular response is generated to both BmVAL-1 and BmALT-2 following vaccination with the multivalent construct. 
Cytokine analysis from proliferated culture supernatants
Multivalent vaccine induces significant protection in mice and jirds:
Above results show that significant IgG antibodies are elicited following vaccination with monovalent and multivalent vaccine preparations. To test if the immune responses elicited following vaccination is protective, we challenged vaccinated animals with live third stage infective larvae (L3) of B. malayi. Since the parasites do not reach to maturity in mice, we used a standard micropore chamber challenge method. 13 These studies showed that 39% to 74% protection can be achieved in mice following immunization with monovalent vaccine (Table 1 ). Protein vaccination gave better results than DNA vaccination. The prime boost regimen gave the best results overall. Vaccination with BmALT-2 gave higher percent of protection compared to BmVAL-1. Similarly, multivalent vaccination regimen gave the 57% to 82% protection compared to the monovalent vaccination regimen. These finding suggested that BmVAL-1 and BmALT-2 synergistically enhance the protective immune responses in vaccinated animals when given as a multivalent vaccine ( Table 1) .
Analysis of the thick blood smear prepared from the control group of jirds on day 80 after challenge showed that all five jirds were positive for microfilaria, whereas, microfilaria were not detected in the peripheral blood of vaccinated jirds (data not shown). Fifteen (15) days later we sacrificed the animals and counted the male and female worms in the peritoneal, pelvic and pleural cavities and compared the results between controls and vaccinated groups (Table 2) . Findings from vaccination of jirds also confirmed that the multivalent prime boost regimen gave the highest rate of protection. No female worms were recovered from the multivalent vaccinated animals.
DISCUSSION
Developing a vaccine against lymphatic filariasis has been challenging due to the complex life cycle of the parasite and the difficulty in obtaining enough parasite materials for research, especially of W. bancrofti. Our laboratory recently developed a phage expression library of different stages of W. bancrofti and B. malayi. 13 Extensive screening of this library with sera from immune individuals yielded several potential candidate antigens. Many of these antigens show significant sequence identity and cross reactivity between W. bancrofti and B. malayi. In this manuscript we analyzed two of the leading vaccine candidates, BmVAL-1 and BmALT-2. Both these antigens were significantly recognized by all EN sera and thus are potential vaccine candidates. Results presented in this study show that multivalent vaccine formulation that combines these two antigens is highly immunogenic than a monovalent vaccine regimen of each antigen separately.
Similarly, a heterologous prime boost approach using DNA prime and protein boost gave significantly higher protection compared to homologous prime boost approach.
Results from our studies show that immunization of mice with BmVAL-1 and BmALT-2 as a multivalent prime boost regimen conferred 82% protection. Since the worms do not mature into adult worms in mice a micropore chamber method was used to evaluate protection. This is a well established method to evaluate protection against B. malayi in mice. 24, 25, 27 The parasite develops into mature adults in jirds. Thus, parasite establishment can be evaluated as a determinant of protection in jirds. Vaccination in jirds also confirmed our results in mice. Multivalent vaccination using a prime boost regimen in jirds also conferred that nearly 85% protection can be achieved. While sterile immunity will be ideal, it is often very difficult to achieve that level of protection with a prophylactic vaccine for any parasitic infection. Nevertheless, close to 85% protection should substantially reduce the incidence of the infection when coupled with treatment of the infected individuals at a much faster rate than multiple application of MDA alone.
The vaccine candidates BmVAL-1 and BmALT-2 are the highly expressed proteins in the third stage larvae of B. malayi. 28 Because of their abundance these proteins are easily available to the host immune system. Previous immunization studies using either of these proteins show that vaccination with each of them can confer significant protection in mouse and jird models. [16] [17] [18] 24 B. malayi Vespid venom allergen homologue-like protein (BmVAH or BmVAL-1) or Ancylostoma secreted protein (ASP), or Sperm Coating protein-like protein (SCP) are all a family of SCP domain containing proteins that are highly immunogenic and are expressed by a number of nematode parasites. 13, [18] [19] [20] 29, 30 Among these ASP has been extensively evaluated for its vaccine potential. 19, 20 Vaccination studies using BmVAL-1 in lymphatic filariasis model show that significant protection can be achieved in mice against challenge infections.
18,30
Although the true function of filarial VAL-1 is not fully understood, VAL-1 homologous are believed to be involved in the establishment of infection and transition to parasitism, as they are very abundant in the excretorysecretory (ES) material of infective larvae. 19 O. volvulus ASP has angiogenic property 22 suggesting that VAL-1 may have potential role in the pathogenesis. VAL-1 also has significant sequence homology with venom allergens from vespid wasps (Ag5) and fire ants (Ag3). 29 Study by Visser et al.
31\
show that VAL-1 and its homologue may have a role in the reproductive development of the male Ostertagia worms. Thus, VAL-1 homologue appears to be important for the establishment and survival of the parasite in the host 19 and may have a possible role in immune evasion. 28 Based on the reports to date, BmVAL-1 appears to be an ideal candidate for vaccine development against lymphatic filariasis.
Another vaccine candidate used in this study is BmALT-2. BmALT-2 and the closely related BmALT-1 together represent about 5% of the total B. malayi L3 cDNA indicating that they are the most abundant proteins in this parasite. 16 BmALT-1 and BmALT-2 are also abundant in the protein secretions of the infective L3. 32 Immunization with Bm-ALT-1 or BmALT-2 can confer approximately 75-76% reduction in worm load. 16, 17 This is probably the only filarial recombinant antigen that can afford this high protection rate. 16 The mechanism of this high protection is not known. However, it is believed that these proteins may play a significant role in host immunomodulation. 28 Significant amounts of BmALT proteins are shown to be released from the glandular stockpiles of L3 larvae. Similar to BmVAL-1 vaccination results, our results with BmALT-2 vaccination also showed that BmALT-2 heterologous vaccination regimen is highly protective than monovalent or homologous regimens.
Since both BmVAL-1 and BmALT-2 conferred significant protection, we combined the two antigens as a multivalent formulation and compared the homologous and heterologous vaccine regimens. These studies showed that a multivalent heterologous vaccine regimen using BmVAL-1/BmALT-2 DNA to prime and BmVAL-1/BmALT-2 protein to boost gave the best protection results. Our findings also showed that combining BmVAL-1 with BmALT-2 can synergistically increase the protection efficiency of both the antigens. Following multivalent vaccination, immunized mice developed comparable titer of antigen-specific antibodies against both the antigen suggesting that BmVAL-1
and BmALT-2 do not interfere in the immunogenicity of the antigens. Thus, the multivalent combination of BmVAL-1 and BmALT-2 is an excellent choice for further vaccine development.
A major contributor to this synergistic effect of these two antigens may be that both the can also bind to FcγRI on the surface of various effector cells that when activated can potentially kill B. malayi larvae. 11, 13, 33, 34 Our previous studies show that antibodies in the sera of endemic normal individuals can participate in the killing of B. malayi L3 through an antibody dependent cell cytotoxicity (ADCC) mechanism.
11,24
Thus, the antigen- Each spot represent sera sample from one individual. The IgG isotype antibody patterns against BmVAL-1 and BmALT-2 were comparable in the sera samples. N=20. Significance -* p < 0.01, ** p < 0.05 compared to control Titer of BmVAL-1 specific IgG antibodies (A) and BmALT-2 specific IgG antibodies (B) in the sera of human subjects. Titer of antigen specific IgG antibodies were determined in sera samples from MF (n=20), CP (n=20) and EN (n=20) subjects using an ELISA. Sera samples from NEN subjects served as controls. Each spot represent sera sample from one individual. The cut off value (mean OD+ 3 times SD of NEN sera) is indicated by a line drawn parallel to X-axis. . Titer of IgG isotype specific antibodies against rBmVAL-1 (A) and rBmALT-2 (B) in the sera samples of endemic normal subjects. Values were determined by specific ELISA for each isotype. Each spot represent sera sample from one individual. The IgG isotype antibody patterns against BmVAL-1 and BmALT-2 were comparable in the sera samples. N=20. 
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